Shockwave Medical (SWAV) Misses Q1 EPS by 10c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Shockwave Medical Reports First Quarter 2020 Financial Results
May 12, 2020 4:04 PM EDTSANTA CLARA, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31, 2020.
Recent Highlights
Recognized revenue of $15.2 million for the first quarter of 2020, representing an increase of 109% over the first quarter of 2019Completed enrollment in CAD III study of IVL for coronary use in the U.S.Completed enrollment in CAD IV pivotal study of IVL for coronary... More